NCT/Study#

NCT02103478 /

ASTX727-01

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of
ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with
Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

DISEASE GROUP:
Leukemia
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: